Drugmakers — including Pfizer Inc, Sanofi SA and GlaxoSmithKline PLC (GSK) — plan to raise prices on more than 300 drugs in the US from yesterday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.
The increases come as drugmakers are reeling from effects of the COVID-19 pandemic, which has reduced doctor visits and demand for some drugs. They are also fighting new drug price cutting rules from US President Donald Trump’s administration, which would reduce the industry’s profitability.
The companies kept their price increases at 10 percent or below, and the largest drug companies to raise prices so far, Pfizer and Sanofi, kept nearly all of their increases at 5 percent or less, said 3 Axis, a consulting firm that works with pharmacists groups, health plans and foundations on drug pricing and supply chain issues.
Photo: EPA-EFE
GSK did raise prices on two vaccines — shingles vaccine Shingrix, and diphtheria, tetanus and pertussis vaccine Pediarix — by 7 percent and 8.6 percent, respectively, 3 Axis said.
Teva Pharmaceuticals Inc hiked prices on 15 drugs, including Austedo, which treats rare neurological disorders, and asthma steroid Qvar, which together grossed more than US$650 million in sales in 2019 and saw price hikes of 5 to 6 percent.
Teva hiked prices for some drugs — including muscle relaxant Amrix and narcolepsy treatment Nuvigil — by as much as 9.4 percent.
More price hikes were expected to be announced yesterday, as well as early this month.
Last year, drugmakers raised prices on more than 860 drugs by an average of about 5 percent, 3 Axis said.
Drug price increases have slowed substantially since 2015, in terms of amount and the number of drugs affected.
The increases come as pharmaceutical companies such as Pfizer are playing hero by developing vaccines for COVID-19 in record time.
The hikes could help make up for lost revenue, as doctors’ visits and new prescriptions plummeted during COVID-19 lockdowns.
Pfizer plans to raise prices on more than 60 drugs by 0.5 to 5 percent, including increases of about 5 percent on some top sellers, such as rheumatoid arthritis treatment Xeljanz, and cancer drugs Ibrance and Inlyta.
Pfizer said that it adjusted the list prices of its drugs by about 1.3 percent across all products in its portfolio, in line with inflation.
“This modest increase is necessary to support investments that allow us to continue to discover new medicines and deliver those breakthroughs to the patients who need them,” spokeswoman Amy Rose said in a statement, pointing in particular to the COVID-19 vaccine that the company developed with Germany’s BioNTech SE.
Pfizer’s net prices have actually fallen for the past three years, it said.
France’s Sanofi plans to increase prices on a number of vaccines by 5 percent or less, and would announce more price increases later this month, spokeswoman Ashleigh Koss said.
None of the company’s price increases would be above 5.1 percent, the expected growth rate of US health spending, she said.
Slashing US prescription drug prices — which are among the highest in the world — was a focus of Trump, after making it a core pledge of his 2016 campaign.
Late last year, Trump issued several executive orders meant to cut prices, but their effect could be limited by legal challenges and other problems.
RETAIL BANKING EXIT: Clients are concerned whether their rights would be protected, while employees were caught by surprise as the bank had just upgraded its services Citibank Taiwan Ltd (花旗台灣) yesterday said that credit card clients could continue using their cards as operations would continue normally until it sells its consumer banking business. As of February, the bank had 2.86 million credit cards in circulation in Taiwan, of which 2.17 million had been used in the past six months, ranking it sixth among all banks, data from the Financial Supervisory Commission showed. Credit card spending by Citibank clients totaled NT$15.66 billion (US$552.6 million) in February, also ranking sixth among banks in Taiwan. Citibank was the only foreign bank that made it into the top six. Customers should not
PANDEMIC EFFECT: Chromebook shipments in the first quarter more than tripled from a year earlier, driven primarily by educational institutions in North America Despite a semiconductor shortage, global PC shipments in the first quarter of this year increased 32 percent from a year earlier, preliminary data from research firm Gartner Inc showed. Shipments in the January-to-March period totaled 69.87 million units from 52.93 million units a year earlier, Gartner said in a report on Monday last week. The quarterly increase in shipments marked the fastest annual growth since it began tracking the PC market in 2000, Gartner said. “This growth should be viewed in the context of two unique factors: comparisons against a pandemic-constrained market and the current global semiconductor shortage,” Gartner research director Mikako Kitagawa
NO MONEY LAUNDERING: Banking Bureau Deputy Director-General Lin Chih-chi said transactions of more than NT$500,000 conducted in cash would need to be reported The Financial Supervisory Commission is to set up new money laundering regulations for the nation’s cryptocurrency exchanges from July 1, requiring them to report transactions valued at more than NT$500,000 (US$17,770), the commission said yesterday. The move came after the Executive Yuan earlier this month demanded that the commission establish regulations to prevent money laundering in the cryptocurrency industry. The cryptocurrency industry includes local trading platforms for cryptocurrencies, cryptocurrency wallet providers and firms that conduct security token offerings, the Executive Yuan said. The commission plans to require cryptocurrency exchanges to report any transaction of more than NT$500,000 conducted in cash, or an equivalent
TREASURY REPORT: A US government report urging the central bank to curtail its foreign-exchange intervention, coupled with soaring exports, might lift the NT dollar The New Taiwan dollar yesterday posted its biggest daily advance since December last year after a report by the US Department of the Treasury last week hinted that US President Joe Biden’s administration could exert greater pressure on Taiwan’s central bank to allow the local currency to appreciate. The NT dollar rose 0.5 percent to close at NT$28.205 against the greenback, and was emerging Asia’s best-performing currency for the day. While the Treasury report on Friday did not label Taiwan as a currency manipulator, it said the US would initiate “enhanced bilateral engagement” to address what it considers as “structural undervaluation”
RSS